<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7429453\results\search\drug\results.xml">
  <result pre="Protocol A multi-centre open-label two-arm randomised superiority clinical trial of" exact="azithromycin" post="versus usual care in ambulatory COVID-19: study protocol for"/>
  <result pre="stated in a credit line to the data. Abstract Background" exact="Azithromycin" post="is an orally active synthetic macrolide antibiotic with a"/>
  <result pre="a potential candidate therapy for pandemic coronavirus disease 2019 (COVID-19)." exact="Azithromycin" post="was widely used to treat severe SARS-CoV and MERS-CoV,"/>
  <result pre="coronavirus infections. Other ongoing trials are exploring short courses of" exact="azithromycin" post="either in early disease, within the first 7â€‰days of"/>
  <result pre="II/III, multi-centre, prospective, open-label, two-arm randomised superiority clinical trial of" exact="azithromycin" post="versus standard care for adults presenting to hospital with"/>
  <result pre="randomised in a 1:1 ratio to usual care or to" exact="azithromycin" post="500â€‰mg orally daily for 14â€‰days with telephone follow-up at"/>
  <result pre="biomarkers. Discussion This trial will determine the clinical utility of" exact="azithromycin" post="in patients with moderately severe, clinically diagnosed COVID-19 and"/>
  <result pre="for accrual on 29 May 2020. Keywords COVID-19 Coronavirus SAR-CoV-2" exact="Azithromycin" post="Macrolide Randomised controlled trial Respiratory failure Mortality Trial Funding"/>
  <result pre="Biomedical Research Centre Funding Oxford University Funding http://dx.doi.org/10.13039/100008648Pfizer Foundation Background" exact="Azithromycin" post="(AZM) is an orally active synthetic macrolide antibiotic with"/>
  <result pre="to treat 1/3 of severe cases of MERS-CoV [1], and" exact="azithromycin" post="has been tried in COVID-19 infection [2] although RCT"/>
  <result pre="data for any coronavirus disease are lacking [3]. Antiviral properties" exact="Azithromycin" post="has well-documented, broad antiviral properties in vitro. Numerous studies"/>
  <result pre="vitro, being shown to reduce viral replication in combination with" exact="hydroxychloroquine" post="[10]. Azithromycin was also associated with a reduced viral"/>
  <result pre="shown to reduce viral replication in combination with hydroxychloroquine [10]." exact="Azithromycin" post="was also associated with a reduced viral load of"/>
  <result pre="receiving some other drugs including fluoroquinolones such as moxifloxacin and" exact="levofloxacin" post="and in patients with ongoing proarrhythmic conditions. Due to"/>
  <result pre="Rationale for design This trial is designed to determine whether" exact="azithromycin" post="is effective in preventing progression to severe respiratory failure"/>
  <result pre="aim is to test the hypothesis that the use of" exact="azithromycin" post="500â€‰mg once daily for 14â€‰days is effective in preventing"/>
  <result pre="objective The primary objective is to compare the effect of" exact="azithromycin" post="in participants with a clinical diagnosis of COVID-19 in"/>
  <result pre="objectives The secondary objectives are to compare the effect of" exact="azithromycin" post="in participants with a PCR-confirmed diagnosis of COVID-19 in"/>
  <result pre="open-label two-arm randomised superiority clinical trial of standard care versus" exact="azithromycin" post="with standard care alone for those presenting to hospital"/>
  <result pre="therapeutic benefit, then this is also essential information to disseminate." exact="Azithromycin" post="is an extremely useful drug for a wide variety"/>
  <result pre="inflammatory cytokines to have a potentially clinically meaningful beneficial effect." exact="Azithromycin" post="is safe and well tolerated. Even in long-term administration"/>
  <result pre="macrolides have a class warning for potential cardiac QT prolongation," exact="azithromycin" post="does not show this effect under experimental conditions [52]."/>
  <result pre="interact with CYP3A4, despite a minor interaction with the anti-coagulant" exact="warfarin" post="[54]. In the large AMAZES RCT, there was no"/>
  <result pre="risk of cardiovascular death of 47 extra deaths/million compared with" exact="amoxicillin" post="(relative risk (RR) for cardiovascular death 2.49 [55], and"/>
  <result pre="LINK Additional file 4. LINK Additional file 5. Abbreviations AZM" exact="Azithromycin" post="BTS British Thoracic Society COVID-19 Coronavirus disease 2019 CURB-65"/>
  <result pre="urea &amp;gt;â€‰7.0 mmol/L, respiratory rate â‰¥â€‰30 breaths/min, blood pressure EDTA" exact="Ethylenediaminetetraacetic acid" post="ePR Electronic patient record IMV Invasive mechanical ventilation MERS"/>
  <result pre="Middle East Respiratory SyndromeInt J Infect Dis20198118419030690213 2.GautretPLagierJParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="bronchial epithelial cellsEur Respir J201036364665420150207 5.SchoglerAKopfBSEdwardsMRJohnstonSLCasaultaCKieningerEet al.Novel antiviral properties of" exact="azithromycin" post="in cystic fibrosis airway epithelial cellsEur Respir J201545242843925359346 6.PorterJDWatsonJRobertsLRGillSKGrovesHDhariwalJet"/>
  <result pre="IFN-augmenting activity in airway epitheliumJ Antimicrob Chemother201671102767278127494903 7.GibsonPGYangIAUphamJWReynoldsPNHodgeSJamesALet al.Effect of" exact="azithromycin" post="on asthma exacerbations and quality of life in adults"/>
  <result pre="Med19961543 Pt 16546608810601 10.AndreaniJLe BideauMDuflotIJardotPRollandCBoxbergerMet al.In vitro testing of combined" exact="hydroxychloroquine" post="and azithromycin on SARS-CoV-2 shows synergistic effectMicrob Pathog202014510422832344177 11.Doan"/>
  <result pre="16546608810601 10.AndreaniJLe BideauMDuflotIJardotPRollandCBoxbergerMet al.In vitro testing of combined hydroxychloroquine and" exact="azithromycin" post="on SARS-CoV-2 shows synergistic effectMicrob Pathog202014510422832344177 11.Doan T, Hinterwirth"/>
  <result pre="Zhong L, et al. Reduction of coronavirus burden with mass" exact="azithromycin" post="distribution. Clin Infect Dis. 2020:ciaa606. 10.1093/cid/ciaa606. 12.Touret F, Gilles"/>
  <result pre="Deng YQ, Li D, Parvatiyar K, Quanquin N, et al." exact="Azithromycin" post="protects against Zika virus infection by upregulating virus-induced type"/>
  <result pre="repurposing screen of approved drugsEmerg Microbes Infect2014312e8426038505 18.KawamuraKIchikadoKTakakiMEguchiYAnanKSugaMAdjunctive therapy with" exact="azithromycin" post="for moderate and severe acute respiratory distress syndrome: a"/>
  <result pre="cellsAm J Physiol Lung Cell Mol Physiol20062901L75L8516085674 33.HuiDYanFChenRHThe effects of" exact="azithromycin" post="on patients with diffuse panbronchiolitis: a retrospective study of"/>
  <result pre="Respir Crit Care Med19981576 Pt 1182918329620913 35.NagaiHShishidoHYonedaRYamaguchiETamuraAKurashimaALong-term low-dose administration of" exact="erythromycin" post="to patients with diffuse panbronchiolitisRespiration.1991583â€&quot;41451491745845 36.WengDWuQChenXQDuYKChenTLiHet al.Azithromycin treats diffuse"/>
  <result pre="Cell Mol Biol200941559060219244203 41.BanjanacMMunic KosVNujicKVrancicMBelamaricDCrnkovicSet al.Anti-inflammatory mechanism of action of" exact="azithromycin" post="in LPS-stimulated J774A.1 cellsPharmacol Res201266435736222766077 42.KhanAASliferTRAraujoFGRemingtonJSEffect of clarithromycin and"/>
  <result pre="action of azithromycin in LPS-stimulated J774A.1 cellsPharmacol Res201266435736222766077 42.KhanAASliferTRAraujoFGRemingtonJSEffect of" exact="clarithromycin" post="and azithromycin on production of cytokines by human monocytesInt"/>
  <result pre="azithromycin in LPS-stimulated J774A.1 cellsPharmacol Res201266435736222766077 42.KhanAASliferTRAraujoFGRemingtonJSEffect of clarithromycin and" exact="azithromycin" post="on production of cytokines by human monocytesInt J Antimicrob"/>
 </snippets>
</snippetsTree>
